Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current classification of gliomas].

Sophie Taillibert1, Marta Pedretti, Marc Sanson

  • 1Fédération de neurologie Mazarin, Bâtiment Mazarin, Hôpital Salpêtrière, 47-83 bd de l'Hôpital, 75013, Paris.

Presse Medicale (Paris, France : 1983)
|December 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acquired genetic and cell-state changes in IDH-mutant glioma progression.

Nature·2026
Same author

Comprehensive characterization of spinal ependymomas in NF2-Schwannomatosis.

Acta neuropathologica communications·2026
Same author

Transverse Relaxation Time Constant of Cystathionine in Human Glioma at 3 T.

Magnetic resonance in medicine·2026
Same author

BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerability.

Cell death discovery·2026
Same author

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

The Lancet. Oncology·2025
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Histologic glioma classification relies on cell morphology, impacting prognosis. New molecular markers like 1p and 19q loss may improve accuracy beyond subjective grading.

Area of Science:

  • Neuro-oncology
  • Histopathology
  • Molecular diagnostics

Context:

  • Glioma classification traditionally relies on histologic morphology.
  • This grading system (WHO grades 1-4) assesses differentiation, cellularity, and mitotic activity.
  • Interobserver variability necessitates integration with clinical and radiological data.

Purpose:

  • To outline the current histologic classification of gliomas.
  • To highlight the prognostic correlation with tumor grade.
  • To introduce emerging molecular markers for refined classification.

Summary:

  • Histologic glioma classification uses cell morphology to grade tumors (pilocytic astrocytoma to glioblastoma).
  • Prognosis correlates with grade, but subjective interpretation requires clinical context.

Related Experiment Videos

  • 1p/19q loss and microarray techniques offer improved prognostic and classification potential.

    • Impact:

    • Enhances understanding of glioma grading and its limitations.
    • Emphasizes the need for integrated diagnostic approaches.
    • Highlights the future direction of glioma classification towards molecular profiling.